ZIA CP010126 10495 (ZIA) | |||
---|---|---|---|
Title | Assessment of Screening Modalities for Gynecologic Cancers | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Wentzensen, Nicolas | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $49,257 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Ovarian Cancer (50.0%) Uterine (50.0%) |
||
Research Type | |||
Exogenous Factors in the Origin and Cause of Cancer Endogenous Factors in the Origin and Cause of Cancer |
|||
Abstract | |||
Currently, there are no convincing early detection approaches for endometrial and ovarian cancers. Although it is well established that some endometrial and ovarian tumors shed cytologically recognizable cells in routinely prepared Pap tests, it is clear that this approach rarely detects occult tumors. Accordingly, efforts to develop means of collecting biological samples that have high patient acceptability, good sensitivity for detecting early disease, and excellent specificity are needed. In this project, we want to assess the feasibility of using alternative sampling techniques in combination with molecular assays to detect endometrial and ovarian cancers. We will compare sampling using a Tampon and a sheathed endometrial brush, the Tao brush. We want to assess the quality of DNA extracted from the different samplers. We will assess the correlations between methylation of somatic DNA for a selected marker panel and cancer status. We wish to include women with suspected endometrial cancer, women with suspected ovarian cancer, and 30 age-matched (+ 5 years) controls without malignancy, all of whom are referred to surgery at the Mayo clinic. We plan to conduct a pilot study of 20 women with confirmed or suspected endometrial cancer, 20 women with confirmed or suspected ovarian cancer, and 30 women treated for benign conditions. DNA will be extracted from samples collected using a vaginal Tampon and an endometrial brushing using an FDA approved device (Tao brush) prior to surgery. A panel of methylation markers will be analyzed from samples yielding sufficient DNA. The results of the methylation analysis will be compared to the final histology for all patients in the study. We will set the detection of methylation at one or more loci in 50% of women in each arm as a technical success. |